New 'Blood Cancer Discoveries Grant Program' supported by a novel 3-way collaboration
(Allen Institute) Seeking to ignite the next major breakthroughs to treat blood cancers, The Leukemia& Lymphoma Society (LLS), The Mark Foundation, and The Paul G. Allen Frontiers Group today announced more than $6.75 million awarded to nine of the most exceptional scientists in the field. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 1, 2020 Category: Biology Source Type: news

What Is the Main Cause of Primary Lymphoma of Bone?
Title: What Is the Main Cause of Primary Lymphoma of Bone?Category: Diseases and ConditionsCreated: 6/30/2020 12:00:00 AMLast Editorial Review: 6/30/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 30, 2020 Category: Cancer & Oncology Source Type: news

Incidence of VTE, Major Bleeding High in Primary CNS Lymphoma
MONDAY, June 29, 2020 -- The incidence of venous thromboembolism (VTE) and major bleeding is high among patients with primary central nervous system lymphoma (PCNSL), according to a study published online June 23 in Leukemia& Lymphoma. Anjlee... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 29, 2020 Category: Pharmaceuticals Source Type: news

XPOVIO (selinexor), FDA Approved for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL), Available at Biologics by McKesson
CARY, N.C., June 29, 2020 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology, rare diseases and other complex therapeutic areas, was selected by Karyopharm Therapeutics, Inc. as a specialty pharmacy provider for XPOVIO® (selinexor) for the treatment of adult patients w... (Source: McKesson News)
Source: McKesson News - June 29, 2020 Category: Information Technology Source Type: news

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
(University of Illinois at Urbana-Champaign, News Bureau) CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia. It modifies a patient's own T-cells by adding a piece of an antibody that recognizes unique features on the surface of cancer cells. In a new study, researchers report that they have dramatically broadened the potential targets of this approach - their engineered T-cells attack a variety of solid-tumor cancer cells from humans and mice. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 29, 2020 Category: Cancer & Oncology Source Type: news

Most American women haven't heard of breast implant-related lymphoma
(Wolters Kluwer Health) Only about 1 out 7 American women have heard about breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) -- an immune system cancer occurring in a small percentage of women with breast implants, according to a new survey. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 25, 2020 Category: International Medicine & Public Health Source Type: news

Roundup Maker to Pay $10 Billion to Settle Cancer Suits
Bayer faced tens of thousands of claims linking the weedkiller to cases of non-Hodgkin ’s lymphoma. Some of the money is set aside for future cases. (Source: NYT Health)
Source: NYT Health - June 25, 2020 Category: Consumer Health News Authors: Patricia Cohen Tags: Hazardous and Toxic Substances Defoliants and Herbicides Suits and Litigation (Civil) Chemicals Agriculture and Farming Biotechnology and Bioengineering Bayer AG Monsanto Company Feinberg, Kenneth R Cancer Source Type: news

Tazemetostat Shows Promise for Pleural Mesothelioma
Five different research groups at the American Society of Clinical Oncology annual meeting last month made presentations on the effectiveness of tazemetostat, a novel protein inhibitor, in fighting various cancers. Pleural mesothelioma was one of those cancers in which clear efficacy was demonstrated, raising hopes again for a future second-line therapy option. “It wasn’t the breakthrough you may be looking for, but there is a set of patients now that can benefit from this treatment for a period of time,” Dr. Marianna Koczywas, medical oncologist at City of Hope cancer treatment and research center in Cal...
Source: Asbestos and Mesothelioma News - June 24, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

A metabolic enzyme drives lymphoma and is a potential drug target
(Memorial Sloan Kettering Cancer Center) Scientists at the Sloan Kettering Institute have found that increased activity of a normal metabolic enzyme can lead to cancer. The enzyme, SHMT2, is a driver of a large portion of B cell lymphomas and could be a potential drug target. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 24, 2020 Category: Cancer & Oncology Source Type: news

Highlights in Non-Hodgkin Lymphoma From ASCO 2020 Highlights in Non-Hodgkin Lymphoma From ASCO 2020
Highlights in non-Hodgkin lymphoma from the ASCO 2020 virtual annual meeting include new data on CAR T cells in relapsed/refractory NHL, and Bcl-2 inhibition and chemoimmunotherapy in Richter syndrome.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 22, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Diffuse Large B Cell Lymphoma Masquerading as GCA Diffuse Large B Cell Lymphoma Masquerading as GCA
This case illustrates an atypical presentation of diffuse large B cell lymphoma initially misdiagnosed as biopsy-negative giant cell arteritis. How was the correct diagnosis finally obtained?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 22, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Karyopharm Announces FDA Approval of Xpovio (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NEWTON, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved oral Xpovio® (selinexor), the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 22, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Gives Thumbs Up to Tazemetostat for Follicular Lymphoma FDA Gives Thumbs Up to Tazemetostat for Follicular Lymphoma
The FDA has granted accelerated approved of the EZH2 inhibitor tazemetostat (Tazverik) for the treatment of relapsed or refractory follicular lymphoma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 19, 2020 Category: Cancer & Oncology Tags: Pharmacist News Alert Source Type: news

How Bad Is Lymphoma Cancer Of Bone?
Title: How Bad Is Lymphoma Cancer Of Bone?Category: Diseases and ConditionsCreated: 6/19/2020 12:00:00 AMLast Editorial Review: 6/19/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 19, 2020 Category: Cancer & Oncology Source Type: news

Early clinical trial supports tumor cell-based vaccine for mantle cell lymphoma
(Rockefeller University Press) A phase I/II clinical trial by researchers at Stanford University suggests that vaccines prepared from a patient's own tumor cells may prevent the incurable blood cancer mantle cell lymphoma (MCL) from returning after treatment. The study, which will be published June 19 in the Journal of Experimental Medicine (JEM), reveals that the vaccines are a safe and effective way to induce the body's immune system to attack any tumor cells that could cause disease relapse. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 19, 2020 Category: Cancer & Oncology Source Type: news

FDA granted accelerated approval to tazemetostat for follicular lymphoma
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 18, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Blood cancer symptoms: Swelling in this part of the body could be a warning sign
BLOOD CANCER - there are three main types: leukaemia, lymphoma and myeloma. Those with non-Hodgkin lymphoma may experience swelling, but where in the body? (Source: Daily Express - Health)
Source: Daily Express - Health - June 18, 2020 Category: Consumer Health News Source Type: news

How Do You Get Non-Hodgkin ’s Lymphoma?
Title: How Do You Get Non-Hodgkin ’s Lymphoma?Category: Diseases and ConditionsCreated: 6/18/2020 12:00:00 AMLast Editorial Review: 6/18/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 18, 2020 Category: Cancer & Oncology Source Type: news

Epizyme Announces U.S. FDA Accelerated Approval of Tazverik (tazemetostat) for Relapsed/Refractory Follicular Lymphoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 18, 2020-- Epizyme, Inc. (Nasdaq:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 18, 2020 Category: Drugs & Pharmacology Source Type: news

Safe to Skip Radiotherapy With Negative PET in Hodgkin Lymphoma Safe to Skip Radiotherapy With Negative PET in Hodgkin Lymphoma
Results from the international HD17 trial suggest that most patients with early stage infavorable Hodgkin lymphoma can be treated with chemotherapy alone.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 15, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, NJ, June 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomized Phase 3 study investigating subcutaneous daratumumab[i] in the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare and potentially fatal disease.[1],[2] The data demonstrated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) resulted in a higher hematologic complete response rate (CR), (53 percent vs. 18 percent [P
Source: Johnson and Johnson - June 15, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Roche presents updated data on novel CD20xCD3 bispecific cancer immunotherapy glofitamab in people with heavily pre-treated non-Hodgkin lymphomas
Basel, 12 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced updated data on one of its investigational CD20xCD3 T-cell engaging bispecific antibodies, glofitamab (formerly known as CD20-TCB), in people with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). Updated results from the phase I dose-escalation NP30179 study [NCT03075696] of glofitamab, administered via intravenous infusion for a fixed-duration of up to 12 21-day cycles, showed durable complete responses (CRs) in heavily pre-treated patients who had received a median of three prior lines of therapy. These data feature in an oral presentation (...
Source: Roche Investor Update - June 12, 2020 Category: Pharmaceuticals Source Type: news

New EPOCH for Adult Patients With Burkitt Lymphoma New EPOCH for Adult Patients With Burkitt Lymphoma
Dose-adjusted EPOCH-R chemotherapy offers similar outcomes in Burkitt lymphoma to high-dose therapy but with lower toxicity, making the traditional approach"unnecessary for cure," say US clinicians.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 11, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

PET/CT confirms breast cancer predicted by blood markers
FDG-PET/CT can detect breast cancer metastases predicted by elevated tumor...Read more on AuntMinnie.comRelated Reading: New PET/CT tracer reliably detects prostate cancer FDA clears Siemens' AI for PET/CT PET/CT pinpoints Hodgkin's lymphoma treatment response Incidental COVID-19 findings seen on routine FDG-PET/CT Digital FDG-PET offers insights into hearing loss (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 11, 2020 Category: Radiology Source Type: news

What Causes Free Peritoneal Fluid?
Discussion Peritoneal fluid is normal. It decreases the friction of the peritoneum covering abdominal and pelvic organs and helps to protect them and allow their movement. A normal amount of peritoneal fluid is expected on radiological evaluation. Increased peritoneal fluid is a continuum and is concerning as a wide variety of pathological causes are associated with it such as abdominal trauma and appendicitis. At the far end of the scale is ascites that is the accumulation of free fluid more than 25 ml. It is usually associated with abdominal distension but fluid must accumulate before distension can occur and therefore i...
Source: PediatricEducation.org - June 8, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Caron A. Jacobson, MD, on the Interim Phase II ZUMA-5 Study Safety and Efficacy Findings
The study evaluated the use of axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2020 Category: Cancer & Oncology Authors: Caron A. Jacobson, MD Source Type: news

Rituximab + Chemo Ups Survival in Pediatric B-Cell Non-Hodgkin Lymphoma
THURSDAY, June 4, 2020 -- For children and adolescents with high-grade, high-risk, mature B-cell non-Hodgkin lymphoma, rituximab added to standard lymphomes malins B (LMB) chemotherapy prolongs event-free survival, according to a study published in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2020 Category: Pharmaceuticals Source Type: news

Phase III results show rituximab excels against pediatric Burkitt lymphoma
(University of Colorado Anschutz Medical Campus) Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported today in the New England Journal of Medicine show 95 percent three-year survival for pediatric patients with advanced B-cell non-Hodgkin lymphoma treated with the addition of anti-cancer immunotherapy rituximab to standard chemotherapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2020 Category: International Medicine & Public Health Source Type: news

A new immunotherapeutic agent for children and adolescents with advanced lymphoma
(Comprehensive Cancer Centre Gustave Roussy) The excellent results of the phase III international paediatric study, Inter-B-NHL ritux 2010, have been published in the New England Journal of Medicine. It establishes a new standard treatment with an improved cure rate for children with advanced non-Hodgkin lymphoma, mainly Burkitt lymphoma. It supports the value of an immunotherapeutic agent, which was authorised in March 2020 by the European Commission for the treatment of a rare childhood cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 3, 2020 Category: Cancer & Oncology Source Type: news

John Kuruvilla, MD, on the Implications of the Phase III KEYNOTE-204 Study
Results from the study indicated that pembrolizumab (Keytruda) was superior to brentuximab vedotin (Adcetris) in patients with relapsed or refractory classic Hodgkin lymphoma (R/R cHL). (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2020 Category: Cancer & Oncology Authors: John Kuruvilla, MD Source Type: news

Therapeutic potential of EBV infection
Targeting MYC or factors that sustain its expression may turn EBV infection into a therapeutic tool for B cell lymphomas. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - June 2, 2020 Category: Science Authors: Ferrarelli, L. K. Tags: STKE Editors ' Choice Source Type: news

Pembrolizumab Prolonged PFS vs Brentuximab in Hodgkin Lymphoma Pembrolizumab Prolonged PFS vs Brentuximab in Hodgkin Lymphoma
Pembrolizumab significantly improved progression-free survival vs brentuximab in a recent phase 3 trial with patients with relapsed or refractory classical Hodgkin lymphoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 1, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Publication in Nature Communications highlights the preclinical development of SYNB1891
(MacDougall Biomedical Communications, Inc.) Synlogic today announced the publication in Nature Communications of preclinical data supporting its first clinical immuno-oncology program, SYNB1891, which is being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors or lymphoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 1, 2020 Category: Cancer & Oncology Source Type: news

Extracoporeal photophoresis cost effective in cutaneous T-cell lymphoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2020 Category: Drugs & Pharmacology Source Type: news

Interim Phase II ZUMA-5 Results Show Promise for Axi-Cel in R/R iNHL
Results showed that axicabtagene ciloleucel demonstrated significant and durable clinical benefit in patients with relapsed or refractory indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

The fight goes on: Clinical trial shows promising new treatment for rare blood cancer
(Nagoya University) Although lymphoma is one of the most common types of blood cancer, it has a rare subtype for which no effective treatment regimens are known. For the first time, Nagoya University researchers and colleagues in Japan have conducted clinical trials for a new treatment protocol and report it to be quite promising. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 30, 2020 Category: International Medicine & Public Health Source Type: news

Off-the-Shelf CAR T-Cell Therapy Shows Promise in Relapsed/Refractory B-Cell Lymphomas
The allogeneic CAR-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, demonstrated clinical responses and manageable toxicity in patients with pretreated large B-cell and follicular lymphomas in the Phase I ALPHA trial. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Conor Killmurray Source Type: news

Pembrolizumab Shows Superior PFS in Relapsed/Refractory Classical Hodgkin Lymphoma
Results of KEYNOTE-204 supports pembrolizumab as new standard of care for patients with classical Hodgkin Lymphoma who have relapsed after autologous stem cell transplant or are ineligible for autologous stem cell transplant. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news

Outcomes Equal for AYA Hodgkin Therapy at Peds, Adult Centers
FRIDAY, May 29, 2020 -- For adolescent and young adult (AYA) patients with Hodgkin lymphoma (HL), treatment strategies differ, but outcomes are equivalent with treatment at pediatric and adult centers, according to a study published online May 22 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 29, 2020 Category: Pharmaceuticals Source Type: news

Updated data demonstrate Roche ’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer
Basel, 29 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented updated data from the pivotal phase III ALEX study, showing an increased five-year survival rate with Alecensa ® (alectinib), compared with crizotinib, in people living with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). These data confirm the longer-term efficacy of Alecensa already demonstrated across three phase III clinical trials. Full findings were presented at the ASCO2 0 Virtual Scientific Programme, on 29 May 2020.“These data further support Alecensa as the standard of care for people with metastatic AL...
Source: Roche Investor Update - May 29, 2020 Category: Pharmaceuticals Source Type: news

Updated data demonstrate Roche ’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer
Basel, 29 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented updated data from the pivotal phase III ALEX study, showing an increased five-year survival rate with Alecensa ® (alectinib), compared with crizotinib, in people living with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). These data confirm the longer-term efficacy of Alecensa already demonstrated across three phase III clinical trials. Full findings were presented at the ASCO2 0 Virtual Scientific Programme, on 29 May 2020.“These data further support Alecensa as the standard of care for people with metastatic AL...
Source: Roche Media News - May 29, 2020 Category: Pharmaceuticals Source Type: news

Stephen Schuster, MD, Gives Advice for Treating Aggressive Lymphomas During COVID-19 Pandemic
Stephen Schuster, MD, talked about the benefits of conducting routine visits remotely during the COVID-19 pandemic, allowing doctors to see and treat more patients safely and efficiently. (Source: CancerNetwork)
Source: CancerNetwork - May 28, 2020 Category: Cancer & Oncology Authors: Stephen Schuster, MD Source Type: news

Study confirms effective, less toxic alternative to standard treatment for adults with Burkitt lymphoma
Dose-adjusted EPOCH-R is already an option for diffuse large B-cell lymphomas and can be administered in an outpatient setting. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - May 26, 2020 Category: American Health Source Type: news

I'm 21 and have had chemotherapy during lockdown. I was one of the lucky ones
Since the start of the Covid-19 crisis, many hospitals have suspended routine cancer surgeries and chemotherapiesCoronavirus – latest updatesSee all our coronavirus coverageWhen I was diagnosed with stage four Hodgkin ’s lymphoma at the beginning of February, my mind immediately turned not to the illness and pain I knew would have to endure, but to the sadness of putting my life on pause. I could never have predicted that the world would end up putting its life on pause with me.My treatment – an intensive chemotherapy regimen – began on 4 March and finished on 12 May, coinciding closely with the UK ...
Source: Guardian Unlimited Science - May 26, 2020 Category: Science Authors: Madeleine Pulman-Jones Tags: Cancer Coronavirus outbreak Society Infectious diseases Medical research Microbiology Science World news Health NHS Hospitals & wellbeing Life and style Students Universities Education Higher education Society Professio Source Type: news

Study confirms effective, less toxic treatment option for adults with Burkitt lymphoma
(NIH/National Cancer Institute) In a new study, an alternative treatment regimen that is less toxic than standard dose-intensive chemotherapy was found to be highly effective for adults with Burkitt lymphoma across all age groups and independent of HIV status. In addition to being better tolerated, the regimen, called dose-adjusted (DA) EPOCH-R, is already an option for diffuse large B-cell lymphomas and can be administered in an outpatient setting. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 26, 2020 Category: Cancer & Oncology Source Type: news

FDA Grants Fast Track Designation for CLR 131 in LPL/WM
The FDA granted fast track designation for CLR 131 in lymphoplasmacytic lymphoma/Waldenstrom ’s macroglobulinemia in patients having received 2 prior treatment regimens or more. (Source: CancerNetwork)
Source: CancerNetwork - May 26, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Stephen Schuster, MD, on Prioritizing Patients with Aggressive Lymphomas During COVID-19 Pandemic
Stephen Schuster, MD, discussed how they are prioritizing patients with more aggressive lymphomas, with emphasis on tumor volume and serum LDH levels during the COVID-19 pandemic. (Source: CancerNetwork)
Source: CancerNetwork - May 25, 2020 Category: Cancer & Oncology Authors: Stephen Schuster, MD Source Type: news

UBC scientist identifies a gene that controls thinness
(University of British Columbia) Why can some people eat as much as they want, and still stay thin? In a study published today in the journal Cell, Life Sciences Institute Director Dr. Josef Penninger and a team of international colleagues report their discovery that a gene called ALK (Anaplastic Lymphoma Kinase) plays a role in resisting weight gain. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 21, 2020 Category: International Medicine & Public Health Source Type: news

Christopher R. Flowers, MD, on Disparities in Lymphoma and Myeloma
The lymphoma and myeloma expert indicated that one of the key ways to address these disparities in lymphoma and myeloma is to improve minority and rural accrual in clinical trials. (Source: CancerNetwork)
Source: CancerNetwork - May 21, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news